Publication number: 20230295227
Abstract: There is provided a composition comprising: (i) a compound of Formula I: (I), or a pharmaceutically acceptable salt thereof, and (ii) a nuclide M, or a pharmaceutically acceptable salt of the compound of Formula I and/or the nuclide M, wherein C is a chelator selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), 1,4,8,11-tetraazacycl otetradecane-1,4,8,11-tetraacetic acid (TETA), diethylenetriaminepentaacetic acid (DTPA), desferrioxamine B (DFO), 1,4,7-Triazacyclononane-1-glutaric acid-4,7-acetic acid (NOTAGA), 2-[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraza-1-cyclododecyl]glutaric acid (DOTAGA and a derivative of any one of the foregoing chelators, L (Formula L) is a linker: (L), wherein m is an integer within the range of from 1 to 20, and X is NH or C(O) and forms an amide bond, i.e.
Type:
Application
Filed:
June 28, 2021
Publication date:
September 21, 2023
Inventors:
Olof ERIKSSON, Olov KORSGREN, Christer WESTERLUND, Michael WAGNER